Biote (BTMD) ROCE % : -4.95% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biote ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biote's annualized ROCE % for the quarter that ended in Mar. 2024 was -4.95%.

Biote ROCE % Historical Data

The historical data trend for Biote's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote ROCE % Chart

Biote Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

152.21

119.45

8.87

5.52

Biote Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial									-79.74	-35.55	82.80	33.76	-4.95

Biote ROCE % Calculation

Biote's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	6.24	/	( ( (111.645 - 18.766)	+	(155.295 - 22.215) )	/ 2 )
	=	6.24	/	( (92.879	+	133.08)	/ 2 )
	=	6.24	/	112.9795
	=	5.52 %

Biote's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-6.656	/	( ( (155.295 - 22.215)	+	(160.108 - 24.057) )	/ 2 )
	=	-6.656	/	( ( 133.08	+	136.051 )	/ 2 )
	=	-6.656	/	134.5655
	=	-4.95 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Biote (NAS:BTMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biote ROCE % Related Terms

Thank you for viewing the detailed overview of Biote's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biote (BTMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038

Website

https://www.biote.com

Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.

Executives

Mary Elizabeth Conlon	officer: General Counsel	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg	10 percent owner	C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc	10 percent owner	757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar	officer: Chief Commercial Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp	10 percent owner	780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar	officer: Chief Financial Officer	7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer	director	C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris	director	11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer	director, officer: President and Director	501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber	director, officer: Chief Executive Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038